新華製藥(000756.SZ):2021年A股股票期權激勵計劃獲華魯控股集團批覆
格隆匯11月25日丨新華製藥(000756.SZ)公佈,公司於近日收到華魯控股集團有限公司《關於山東新華製藥股份有限公司實施股權激勵的批覆》(華魯控股發[2021]80號),主要內容如下:
根據國務院國資委、財政部《關於印發<國有控股上市公司(境內)實施股權激勵試行辦法>的通知》(國資發分配〔2006〕175號)、省國資委《關於進一步完善省屬企業控股上市公司股權激勵的意見》(魯國資〔2021〕3號)等有關規定,經研究並經山東省國資委備案,原則同意新華製藥實施2021年A股股票期權激勵計劃。此次股權激勵計劃經新華製藥股東大會審議通過後實施。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.